BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone
(BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.